Products with Neuroprotection bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1929 | Cochlearine |
| 1. Cochlearines A can significantly inhibit Cav3.1 T-type calcium channel (TTCC) and show noticeable selectivity against Cav1.2, Cav2.1, Cav2.2, and Kv11.1 (hERG) channels; and TTCC inhibitors hold great potential for the treatment of a variety of neurological disorders. | |
| BCN1945 | Tigloidine |
| 1.Tigloidine hydrobromide, a naturally occuring analogue of atropine, could be as a substitute for atropine in the treatment of parkinsonism. | |
| BCN2080 | Emiline |
| 1. (±)-Emiline displays good neuroprotective effect against the corticosterone-induced apoptosis in PC12 cells. | |
| BCN2167 | Fingolimod hydrochloride |
| Fingolimod hydrochloride is an oral sphingosine-1-phosphate analogue that was approved by the FDA in 2010 for the treatment of relapsing forms of multiple sclerosis (MS). Fingolimod hydrochloride , a pak1 activator, can inhibit astemizole-induced hypertrophy and cytotoxicity in H9c2 cells, suggests that antihistamine-induced cardiac adverse effects are associated with pak1 expression and function.The gels containing 0.50% fingolimod hydrochloride (FNGL) and FNGL 0.50% plus 6% colloidal oatmeal have potential for the treatment of atopic dermatitis (AD). | |
| BCN2194 | beta-Estradiol |
| Estradiol, or more precisely, 17β-estradiol, is a human sex hormone and steroid, and the primary female sex hormone. Beta-estradiol has been considered to be a neurotrophic agent, beta-estradiol at a dose of 0.25 microg/day prevents ischemia-induced learning disability and neuronal loss at early stages after transient forebrain ischemia, possibly via a receptor-mediated pathway without attenuating free radical neurotoxicity. | |
